CPRX
Price:
$21.62
Market Cap:
$2.58B
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; a...[Read more]
Industry
Biotechnology
IPO Date
2006-11-08
Stock Exchange
NASDAQ
Ticker
CPRX
According to Catalyst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 18.32. This represents a change of 27.42% compared to the average of 14.38 of the last 4 quarters.
The mean historical PE Ratio of Catalyst Pharmaceuticals, Inc. over the last ten years is 3.17. The current 18.32 PE Ratio has changed 57.68% with respect to the historical average. Over the past ten years (40 quarters), CPRX's PE Ratio was at its highest in in the March 2024 quarter at 19.75. The PE Ratio was at its lowest in in the March 2019 quarter at -198.08.
Average
3.17
Median
-0.10
Minimum
-18.22
Maximum
25.02
Discovering the peaks and valleys of Catalyst Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 284.45%
Maximum Annual PE Ratio = 25.02
Minimum Annual Increase = -308.98%
Minimum Annual PE Ratio = -18.22
Year | PE Ratio | Change |
---|---|---|
2023 | 25.02 | 8.10% |
2022 | 23.14 | 30.56% |
2021 | 17.73 | 284.45% |
2020 | 4.61 | -61.93% |
2019 | 12.11 | -308.98% |
2018 | -5.80 | -68.19% |
2017 | -18.22 | 278.42% |
2016 | -4.82 | -50.82% |
2015 | -9.79 | -20.29% |
2014 | -12.28 | 68.45% |
The current PE Ratio of Catalyst Pharmaceuticals, Inc. (CPRX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
21.96
5-year avg
16.52
10-year avg
3.17
Catalyst Pharmaceuticals, Inc.’s PE Ratio is greater than Day One Biopharmaceuticals, Inc. (-14.52), greater than Terns Pharmaceuticals, Inc. (-5.12), greater than X4 Pharmaceuticals, Inc. (-6.95), greater than Inozyme Pharma, Inc. (-1.92), greater than Mereo BioPharma Group plc (-13.89), less than Exelixis, Inc. (20.69), greater than TG Therapeutics, Inc. (-324.87), greater than Viking Therapeutics, Inc. (-47.37), greater than Madrigal Pharmaceuticals, Inc. (-13.08), greater than BioXcel Therapeutics, Inc. (-0.21), greater than Axsome Therapeutics, Inc. (-13.47), less than Incyte Corporation (414.59), less than ImmunoGen, Inc. (322.18), less than Sarepta Therapeutics, Inc. (95.43), less than ACADIA Pharmaceuticals Inc. (22.05), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than Hepion Pharmaceuticals, Inc. (-0.15), greater than Akero Therapeutics, Inc. (-8.36), greater than Reata Pharmaceuticals, Inc. (-20.07),
Company | PE Ratio | Market cap |
---|---|---|
-14.52 | $1.28B | |
-5.12 | $492.65M | |
-6.95 | $98.92M | |
-1.92 | $188.22M | |
-13.89 | $589.54M | |
20.69 | $9.66B | |
-324.87 | $5.01B | |
-47.37 | $4.72B | |
-13.08 | $6.80B | |
-0.21 | $17.42M | |
-13.47 | $4.22B | |
414.59 | $13.47B | |
322.18 | $8.73B | |
95.43 | $11.64B | |
22.05 | $2.84B | |
-91.78 | $794.69M | |
-0.15 | $3.48M | |
-8.36 | $1.99B | |
-20.07 | $6.57B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Catalyst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Catalyst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Catalyst Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Catalyst Pharmaceuticals, Inc. (CPRX)?
What is the highest PE Ratio for Catalyst Pharmaceuticals, Inc. (CPRX)?
What is the 3-year average PE Ratio for Catalyst Pharmaceuticals, Inc. (CPRX)?
What is the 5-year average PE Ratio for Catalyst Pharmaceuticals, Inc. (CPRX)?
How does the current PE Ratio for Catalyst Pharmaceuticals, Inc. (CPRX) compare to its historical average?